FrancophonIA/ELRC3.0 huggingface dataset:
English: Further to discussions at the CHMP October 2004 plenary meeting, the European Commission recommended that this public health issue on all aspects of cardiovascular safety including thrombotic events and cardio-renal events is the subject of Community referrals under Article 31 of Directive 2001/83/EC, as amended regarding decentrally authorised products containing celecoxib, etoricoxib and lumiracoxib and subject to a review procedure under Article 18 of Council Regulation (EEC) No 2309/93, as amended regarding the centrally authorised products containing celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn), which were started in November 2004.
Latvian: Pec diskusijam Cilvekiem paredzeto zalu komitejas (CHMP), 2004. gada oktobra sanaksme, Eiropas Komisija ieteica šo sabiedribas veselibas problemu parskatit no visiem kardiovaskulara nekaitiguma aspektiem, ieskaitot trombu veidošanas gadijumus un sirds un nieru paradibas, saskana ar Kopienas parskatišanas noteikumiem, kas izklastiti direktivas 2001/83/EK 31. panta ar papildinajumiem attieciba uz necentralizeti registretam zalem, kas satur celecoxib, etoricoxib un lumiracoxib un veikt parskatišanas proceduru saskana ar Padomes Regulas (EEK)
English: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use ofcelecoxib (see 4.8).
Latvian: Sanemti loti reti zinojumi par nopietnam adas reakcijam, dažas no tam fatalas, tostarp, eksfoliativu dermatitu, Stivensa-Džonsona sindromu un toksisko epidermalo nekrolizi pacientiem, kuri lietoja celekoksibu (skatit apakšpunktu 4.8).
English: Osteoarthritis: The usual recommended daily dose is 200 mg taken once daily or in two divided doses.
Latvian: Osteoartrits: Parasta ieteicama dienas deva ir 200 mg, kas ienemama viena reize vai dalita divam ienemšanas reizem.
English: Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses from 50 mg-400 mg BID).
Latvian: Veikti pieci randomizeti, dubultakli, kontroleti petijumi, ietverot kunga-zarnu trakta augšejas dalas planveida endoskopiju, kuros piedalijas ap 4500 pacientu bez culam sakumstavokli (celekoksiba devas bija no 50 lidz 400 mg divas reizes diena).
English: {INVENTED NAME, see Annex I } 200 mg capsule, hard.
Latvian: {IZGUDROTAIS NOSAUKUMS, skatit pielikumu I}, 100 mg cietas kapsulas {IZGUDROTAIS NOSAUKUMS, skatit pielikumu I}, 200 mg cietas kapsulas
English: NSAIDs may reduce the effect of diuretics and antihypertensive medicinal products.
Latvian: NSPL var mazinat diuretisko lidzeklu un antihipertensivo zalu efektivitati.
English: For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually.
Latvian: Celekoksiba grupa primarais galapunkts - komplicetu culu (definetu ka gastrointestinala asinošana, perforacija vai obstrukcija) biežums butiski neatškiras no ibuprofena grupas vai diklofenaka grupas.
English: For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95% CI 0.45-0.97 but not between celecoxib and diclofenac.
Latvian: Celekoksiba grupa kombinetais galapunkts - komplicetu un simptomatisku culu biežums, bija butiski zemaks salidzinot ar NSPIL grupu, relativais risks 0,66, 95 % ticamibas intervals 0,45 - 0,97, bet ne starp celekoksiba un diklofenaka grupam.
English: Metabolism and nutrition disorders Uncommon: hyperkalaemia
Latvian: Metabolisma un barošanas traucejumi Retak: hiperkaliemija
English: Experience in such patients is limited to cirrhotic patients (See 4.3, 4.4 and 5.2).
Latvian: Pieredze šadu pacientu arstešana aprobežojas vienigi ar aknu cirozes slimniekiem (sk. 4.3., 4.4.un 5.2.).
English: Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment.
Latvian: Paaugstinatu šo reakciju risku pacientiem parasti novero terapijas kursa sakuma: lielakaja dala gadijumu reakcijas sakas terapijas pirmaja menesi.
English: The inter-subject variability in the exposure of celecoxib is about 10-fold.
Latvian: Celekoksiba ekspozicija dažadiem cilvekiem var atškirties par aptuveni 10 reizem.
English: Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Latvian: Zinama sirds išemiska slimiba, perifero arteriju slimiba un/vai cerebrovaskulara slimiba.
English: Cardiac disorders Uncommon: myocardial infarction*, heart failure, palpitations
Latvian: Sirds funkcijas traucejumi Retak: miokarda infarkts*, sirds mazspeja, sirdsklauves
English: In patients on concurrent therapy with warfarin, serious bleeding events have occurred.
Latvian: Pacientiem, kuri vienlaikus sanemuši terapiju ar varfarinu, noverotas smagu asinošanu epizodes.
English: Also for the combined NSAID group there was no statically significant difference for complicated ulcers (relative risk 0,77, 95 % CI 0.41-1.46, based on entire study duration).
Latvian: Salidzinot ari ar kombinetu NSPIL grupu nebija statistiski ticamas atškiribas komplicetu culu biežuma (relativais risks 0,77, 95 % ticamibas intervals 0,41 - 1,46, balstits uz pilnu petijuma laiku).
English: Opaque, white with two gold bands marked 7767 and 200 (INVENTED NAME 200 mg).
Latvian: Necaurspidigas, baltas kapsulas ar zeltitu apmali, uz tam markejums 7767 un 200 (IZGUDROTAIS NOSAUKUMS
English: Between November 2004 and June 2005, the MAH made oral explanations to the CHMP on cardiovascular and skin safety aspects for celecoxib on 18 January, 15 February, and 25 May 2005.
Latvian: Laika posma no 2004. g. novembra lidz 2005. gada junijam (2005. gada 18. janvari, 15. februari un 25. maija) registracijas apliecibas ipašnieks sniedza CHMP mutiskus zinojumus par celecoxib kardiovaskulara un adas nekaitiguma aspektiem.
English: The increased risk became apparent after approximately 1 year of treatment.
Latvian: Riska pieaugums kluva acimredzams apmeram pec 1 gada terapijas.
English: Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib Cmax of 60% and in AUC of 130%.
Latvian: Celekoksiba (atseviškas 200 mg lielas devas) un CYP2C9 inhibitora flukonazola (200 mg reizi diena) vienlaiciga lietošana izraisija celekoksiba Cmax 60% un AUC 130% pieaugumu.
English: No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.
Latvian: Nekada statistiski nozimiga COX-1 inhibicija (novertets pec tromboksana B2 [TxB2] veidošanas kavejuma ex vivo) šaja devu diapazona veseliem brivpratigajiem netika noverota.
English: Celecoxib is an inhibitor of CYP2D6.
Latvian: Celekoksibs ir CYP2D6 inhibitors.
English: The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.
Latvian: Šo gadijumu butiski zemaka sastopamiba tika noverota lietojot cele koksibu ar vai bez lidztekus acetilsalicilskabes lietošanu.
English: Celecoxib at daily doses of 200 mg - 400 mg provided pain relief within 24 hours of dosing.
Latvian: Celekoksibs dienas deva 200 mg - 400 mg uzradija sapju atvieglojumu 24 stundas no devas ienemšanas briža.
English: Spain
Latvian: Spanija
English: Preliminary data from the other two long-term studies did not show a significantly increased cardiovascular risk with celecoxib 200mg BID and 400mg QD compared to placebo.
Latvian: P irmatnejie dati no citiem diviem ilgtermina petijumiem neuzrada ticami paaugstinatu kardiovaskularo risku, lietojot celekoksibu 200 mg divas reizes un 400 mg vienu reizi, salidzinajuma ar placebo.
English: Particular caution should be exercised in elderly with a body weight less than 50 kg. (See 4.4 and 5.2).
Latvian: Ipaša uzmaniba ir javelta gados vecakiem pacientiem, kuru kermena masa ir zem par 50 kg (skatit apakšpunktus 4.4 un 5.2).
English: The incidence of clinically significant decreases in haemoglobin (>2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48.
Latvian: Pacientiem celekoksiba grupa bija butiski zemaka kliniski nozimiga hemoglobina samazinašanas incidence, apstiprinata atkartotos merijumos, salidzinot ar NSPIL grupu, relativais risks 0,29, 95 % ticamibas intervals 0,17 - 0,48.
English: Diaphragmatic hernia was also seen in a peri-post natal toxicity study in rats, which included exposure during the organogenetic period.
Latvian: Diafragmalas hernijas veidošanas noverota ari perinatala un postnatala toksiskuma petijuma ar žurkam, kurš ietvera ekspoziciju organogenezes perioda.
English: In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in Cmax of 16% and in AUC of 18% of lithium.
Latvian: Veseliem subjektiem celekoksiba 200 mg divas reizes diena lidztekus lietošana ar litiju 450 mg divas reizes diena, radija litija videji Cmax 16% un AUC 18% pieaugumu.
English: The MAH commits to performing a global CV study to confirm long term CV safety of Celecoxib.
Latvian: Registracijas apliecibas ipašnieks (MAH) apnemas veikt globalu kardiovaskularo petijumu, lai apstiprinatu Celecoxib ilgtermina kardiovaskularo drošibu.
English: In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the maximum recommended daily human dose was 3X.
Latvian: Šaja petijuma sistemiskas ekspozicijas viszemakais robežlimenis, pie kura ši anomalija vel radas kaut vienam dzivniekam, bija 3 reizes lielaks par maksimalo ieteicamo dienas devu cilvekam.
English: - Addition of a warning for prescribers to exercise caution when prescribing NSAIDs, including celecoxib, in combination with ACE inhibitors or angiotensin II receptor antagonists.
Latvian: - pievienots bridinajums zalu izrakstitajiem but piesardzigiem, indicejot nesteroidas pretiekaisuma zales (NSAIDs), tai skaita celecoxib kopa ar angiotenzina konvertejošo enzimu (ACE) inhibitoriem vai angiotenzina II tipa receptora antagonistiem.
English: UK
Latvian: Lielbritanija
English: Coadministration of NSAIDs and cyclosporin or tacrolimus have been suggested to increase the nephrotoxic effect of cyclosporin and tacrolimus.
Latvian: Pastav noradijumi, ka NSPIL ievadišana kopa ar ciklosporiniem vai takrolimu pastiprina ciklosporinu un takrolima nefrotoksisko efektu.
English: The changes of the Product Information related to the CV can be summarised as follows: - Addition of a statement that decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks.
Latvian: Izmainas zalu apraksta saistiba ar kardiovaskularo iedarbibu var apkopot šadi: - pazinojuma papildinajums, ka selektivais COX-2 inhibitors janozime pacientam, nemot vera katra individualo kopejo riska vertejumu.
English: Slovenia
Latvian: Slovenija
English: 6.1 List of excipients
Latvian: 6.1 Paligvielu saraksts
English: The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (4.3, 4.4, 4.8 and 5.1).
Latvian: Pacientiem, ipaši ar osteoartritu, periodiski jaizverte simptomu noveršanas nepieciešamiba un atbildes reakcija uz terapiju (skatit apakšpunktus 4.3, 4.4, 4.8 un 5.1).
English: Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.
Latvian: Celekoksibam nav kliniski nozimigas ietekmes uz tolbutamida (CYP2D9 substrats) vai glibenklamida farmakokinetiku.
English: *In a pooled analysis of 20 placebo-controlled studies with duration greater than 2 weeks up to 1 year in patients with OA and RA, the excess rate of myocardial infarction in patients treated with celecoxib 200 or 400 mg daily over placebo was 0.7 events per 1000 patients (Rare) and there was no excess of strokes.
Latvian: *Divu nedelu lidz 1 gadam ilgu 20 placebo kontroleto petijumu kopeja analize, pacientiem ar osteoartritu un reimatoido artritu, kurus arsteja ar celekoksibu 200 mg vai 400 mg diena, miokarda infarkts bija 0,7 gadijumos uz 1000 pacientiem (Reti), kas ir vairak neka placebo, bet insultu skaits nebija lielaks.
English: COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.
Latvian: COX-2 inhibitori nomac sistemiska (un tadejadi, iespejams, ari endoteliala) prostaciklina veidošanos, neietekmejot trombocitos esošo tromboksanu.
English: Pharmacokinetic interactions
Latvian: Farmakokinetiska mijiedarbiba
English: 6.6 Instructions for use and handling, and disposal (if appropriate) No special requirements.
Latvian: 6.6 Noradijumi par sagatavošanu lietošanai un iznicinašanu Nav ipašu prasibu.
English: In the same studies, the excess rate for clearly identified ischaemic stroke for the 400 mg daily dose (not including events that were haemorrhagic or of unknown aetiology) was 0.5 event per 1000 over 3 years (Rare).
Latvian: Tajos pašos petijumos ilgakos par 3 gadiem lietojot 400 mg devu diena, skaidri identificets išemisks insults (netika ieklauti hemoragiski un nezinamas etiologijas gadijumi) bija 0,5 gadijumos uz 1000 pacientiem (Reti).
English: Elderly >65 years: As in younger adults, 200 mg per day should be used initially.
Latvian: Gados vecaki cilveki (>65 gadi): Tapat ka jaunakiem pieaugušajiem, sakuma jalieto 200 mg diena.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.
Latvian: Šis zales nevajadzetu lietot pacientiem ar retu iedzimtu galaktozes nepanesibu, ar Lapp laktazes deficitu vai glikozes-galaktozes malabsorbciju.
English: To provide all ongoing epidemiological studies in accordance with updates on on-going post marketing activities (for example, within PSURs for Celebra).
Latvian: Informe par visiem notiekošajiem epidemiologiskajiem petijumiem, ieverojot jaunako informaciju par notiekošajam pecregistracijas darbibam (piemeram, PSUR attieciba uz Celebra).
English: Children: Celecoxib is not indicated for use in children.
Latvian: Berni: Celekoksibs berniem nav indicets.
English: Hungary
Latvian: Ungarija
English: Celecoxib is metabolised in the liver by hydroxylation, oxidation and some glucuronidation.
Latvian: Celekoksibs metabolizejas aknas hidroksilacijas, oksidacijas un pa dalai glikuronidacijas cela.
English: There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).
Latvian: Tiek veicinats gastrointestinalo blakusparadibu paaugstinats risks (gastrointestinala culas slimiba vai citas gastrointestinalas komplikacijas), ja celekoksibu, lieto kombinacija ar acetilsalicilskabi (pat mazas devas).
English: 4.4 Special warnings and special precautions for use
Latvian: 4.4 Ipaši bridinajumi un piesardziba lietošana
English: 4.9 Overdose
Latvian: 4.9 Pardozešana
English: Renal impairment: Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution.
Latvian: Nieru darbibas traucejumi: Pieredze celekoksiba lietošana pacientiem ar maz izteiktiem vai mereni izteiktiem nieru funkciju traucejumiem ir ierobežota, tadel šadi pacienti arstejami piesardzigi.
English: However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.
Latvian: Tomer dažos nelielos multiplu devu petijumos veseliem subjektiem 600 mg celekoksiba divas reizes diena (tris reizes parsniedz maksimalo ieteicamo devu), salidzinajuma ar placebo neietekmeja ne trombocitu agregaciju, ne asinošanas laiku.
English: Follow-up measures of the Marketing Authorisation Holder As requested by the CHMP, the MAH agreed to submit the follow-up measures as listed below:
Latvian: Registracijas apliecibas ipašnieka papildus pasakumi Pec Cilvekiem paredzeto zalu komitejas (CHMP) pieprasijuma, Registracijas apliecibas ipašnieks (MAH) piekrita iesniegt informaciju par šadiem, zemak uzskaititajiem, papildus pasakumiem:
English: Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.
Latvian: Pacientiem ir jasanem adekvata hidratacija, jaapsver nieru funkciju monitorešana uzsakot paralelo terapiju, ka ari periodiski tas gaita.
English: Pharmacological activity resides in the parent drug.
Latvian: Farmakologiska aktivitate piemit neparveidotam savienojumam.
English: Ongoing Clinical Trials: Preliminary safety information from three long-term studies involving patients with Sporadic Adenomatous Polyps or who were predisposed to developing Alzheimer's disease treated with celecoxib is available.
Latvian: Kliniskie petijumi, kas turpinas: Ir pieejama pirmatneja informacija par celekoksiba terapijas drošibu tris ilgermina petijumos pacientiem ar sporadiskiem adenomatoziem polipiem vai pacientiem, kuri predisponeti Alzheimer slimibas attistibai.
English: The potential for human risk in pregnancy is unknown, but cannot be excluded.
Latvian: Potencialais risks cilvekam grutniecibas laika nav zinams, tacu izslegt to nevar.
English: COX-2 is the isoform of the enzyme that has been shown to be induced by proinflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
Latvian: Pieradits, ka enzima izoforma COX-2 induce iekaisumu veicinošie faktori un tieši ta ir atbildiga par sapju, iekaisuma un drudža prostanoido mediatoru sintezi.
English: Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma.
Latvian: Celekoksibs izdalas zidošu žurku matišu piena tada paša koncentracija, kada tas ir plazma.
English: Patients known to be CYP2C9 poor metabolisers should be treated with caution (see 5.2.
Latvian: Pacienti, kuriem ir pavajinata CYP 2C9 aktivitate, jaarste seviški piesardzigi (skatit apakšpunktu 5.2).
English: However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two drugs.
Latvian: Tomer, butu javeic adekvats metotreksata saistitas toksicitates monitorings, kad šis zales lieto kombinacija.
English: Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
Latvian: Pacienti, kuriem pec acetilsalicilskabes vai nesteroida pretiekaisuma lidzekla (NSPIL), tai skaita COX-2 (ciklooksigenazes-2) inhibitora ienemšanas radusies astma, akuts rinits, deguna polipi, angioneirotiska tuska, natrene vai cita alergiska tipa reakcija.
English: Examples of drugs which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.
Latvian: Preparati, kurus metabolize CYP2C19, ir, piemeram, diazepams, citaloprams un imipramins.
English: Rheumatoid arthritis: The initial recommended daily dose is 200 mg taken in two divided doses.
Latvian: Reimatoidais artrits: Sakuma ieteicama dienas deva ir 200 mg, ko sadala divam ienemšanas reizem.
English: The plasma concentrations of drugs that are substrates of this enzyme may be increased when celecoxib is used concomitantly.
Latvian: Ja celekoksibs tiek lietots vienlaikus ar preparatiem, kas ir ši enzima substrati, to koncentracija plazma var but paaugstinata.
English: Infections and infestations Common: sinusitis, upper respiratory tract infection Uncommon: urinary tract infection
Latvian: Infekcijas un parazitozes Bieži: sinusits, augšeja elpošanas trakta infekcijas
English: Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.
Latvian: Celekoksibs tapat ka citi prostaglandinu sintezi kavetaji medikamenti var izraisit dzemdibu darbibas vajumu un ductus arteriosus priekšlaicigu slegšanos pedeja trimestri.
English: Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications.
Latvian: Pacientiem, kuri lidztekus lieto varfarinu vai citus antikoagulantus, jakontrole antikoagulejošas terapijas efekts, it ipaši sakot arstešanos ar celekoksibu vai mainot ta devu, jo šiem pacientiem ir paaugstinats hemoragisku komplikaciju risks.
English: Examples of drugs which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, antiarrhythmic drugs, etc.
Latvian: Preparati, kurus metabolize CYP2D6, ir, piemeram, antidepresanti (tricikliskie antidepresanti un selektivie serotonina atpakalsaistišanas inhibitori), neiroleptiskie lidzekli, antiaritmiskie preparati u.c.
English: Clinical 5
Latvian: 5. kliniskais posms
English: Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention.
Latvian: Ši iemesla del celekoksibs lietojams piesardzigi pacientiem, kuriem anamneze ir sirds mazspeja, kreisa ventrikula disfunkcija vai hipertensija, ka ari pacientiem, kuriem ir jel kadas citas izcelsmes tuska, jo prostaglandinu inhibicijas rezultata var pavajinaties nieru funkcija un rasties škidruma retence.
English: Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.
Latvian: Jaievero piesardziba, arstejot pacientus, kam pastav seviški augsts NSPIL izraisitu gastrointestinalo komplikaciju risks, tie ir: gados vecaki cilveki, pacienti, kuri vienlaikus lieto kadus citus NSPIL vai acetilsalicilskabi, ka ari pacienti ar gastrointestinalu ulceraciju un GI asinošanu anamneze.
English: Musculoskeletal and connective tissue disorders Uncommon: leg cramps
Latvian: Skeleta-muskulu un saistaudu sistemas bojajumi Retak: krampji kajas
English: Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in Cmax of 53% and in AUC of 26% of celecoxib.
Latvian: Pacientiem ar vieglu aknu bojajumu celekoksiba videjais Cmax pieauga par 53 % un AUC par 26 %, salidzinot ar veseliem subjektiem, kam aknu funkcija ir normala.